Protalix BioTherapeutics Issues 2020 Letter to Shareholders
- Wednesday, December 30, 2020, 7:02
- Finance
- Add a comment
CARMIEL, Israel, Dec. 30, 2020 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant…
About the Author
adminasapcorp has written 38957 stories on this site.